Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study

Ishii, Makoto; Terai, Hideki; Kabata, Hiroki; Masaki, Katsunori; Chubachi, Shotaro; Tateno, Hiroki; Nakamura, Morio; Nishio, Kazumi; Koh, Hidefumi; Watanabe, Risa; Ueda, Soichiro; Terashima, Takeshi; Suzuki, Yusuke; Yagi, Kazuma; Miyao, Naoki; Minematsu, Naoto; Inoue, Takashi; Nakachi, Ichiro; Namkoong, Ho; Okamori, Satoshi; Ikemura, Shinnosuke; Kamata, Hirofumi; Yasuda, Hiroyuki; Kawada, Ichiro; Hasegawa, Naoki; Fukunaga, Koichi

doi:10.1016/j.jinf.2020.08.052

Cited by 28 publications

(39 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This suggests existence of populational heterogeneity in the impacts of causal links from the baseline clinical manifestations to COVID-19 susceptibility. Hyperuricemia is reported as one of the major risk factors of severe COVID-19 in Japan 18 , which is consistent with a Japanesespecific causal inference of UA and gout in the Japanese MR analysis. There exist controversial discussions on the risk of SLE patients on COVID-19 infection 38,39 .…”

Section: Causal Inference On Covid-19 By Cross-population Mendelian Randomizationsupporting

confidence: 82%

See 1 more Smart Citation

Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

Namkoong

Edahiro

Fukunaga

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

To elucidate the host genetic loci affecting severity of SARS-CoV-2 infection, or Coronavirus disease 2019 (COVID-19), is an emerging issue in the face of the current devastating pandemic. Here, we report a genome-wide association study (GWAS) of COVID-19 in a Japanese population led by the Japan COVID-19 Task Force, as one of the initial discovery GWAS studies performed on a non-European population. Enrolling a total of 2,393 cases and 3,289 controls, we not only replicated previously reported COVID-19 risk variants (e.g., LZTFL1, FOXP4, ABO, and IFNAR2), but also found a variant on 5p35 (rs60200309-A at DOCK2) that was significantly associated with severe COVID-19 in younger (<65 years of age) patients with a genome-wide significant p-value of 1.2 × 10-8 (odds ratio = 2.01, 95% confidence interval = 1.58-2.55). This risk allele was prevalent in East Asians, including Japanese (minor allele frequency [MAF] = 0.097), but rarely found in Europeans. Cross-population Mendelian randomization analysis made a causal inference of a number of complex human traits on COVID-19. In particular, obesity had a significant impact on severe COVID-19. The presence of the population-specific risk allele underscores the need of non-European studies of COVID-19 host genetics.

show abstract

Section: Causal Inference On Covid-19 By Cross-population Mendelian Randomizationsupporting

confidence: 82%

“…Odds ratios of the ABO blood types in the Japanese population are indicated. [3][4][5][6]18,38,39 . Lists of the GWAS studies of the exposure phenotypes are in Supplementary Table 9.…”

Section: Figure 4 Forest Plots Of the Abo Blood Type Associations With Covid-19 In Japanesementioning

confidence: 99%

Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

Namkoong

Edahiro

Fukunaga

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work. Chen Q et al(2020) [11] Taizhou, Zhejiang, Chen T et al(2020) [12] Wuhan, China [13] Padova,Italy [14] New York, USA [15] Nationwide, China Huang C et al(2020) [16] Wuhan, China [18] London, England [20] Nationwide, Japan [22] Chongqing, China [23] Fuyang, Anhui, [26] Nationwide, China [27] Single-center,Observational…”

Section: Discussionmentioning

confidence: 99%

“…Zhan T et al(2020) [28] Wuhan, China Chen Q et al(2020) [11] Taizhou, Zhejiang, Chen T et al(2020) [12] Wuhan, China [13] Padova, Italy [14] New York, USA Guan W et al(2020) [15] Nationwide, China [18] London, England [20] Nationwide, Japan [22] Chongqing, China [26] Observational Yang L et al(2020) [27] Yichang, China (2020) [3] COVID-19 and smoking: A systematic review of the evidence USA 5 retrospective studies; Lippi G et al…”

Section: Discussionmentioning

confidence: 99%

Association of smoking and cardiovascular disease with disease progression in COVID-19: a systematic review and meta-analysis

2021

View full text Add to dashboard Cite

The aim of this study was to systematically assess the association between smoking and cardiovascular disease and disease progression among novel coronavirus pneumonia (COVID-19) cases. PubMed database and Cochrane Library database were searched by computer to seek the epidemiological data of COVID-19 cases and literatures regarding cardiovascular diseases from 1 Jan to 6 October 2020. Two researchers independently conducted literature screening, data collection and the assessment of the risk of bias of the studies included. RevMan 5.2 software was employed for meta-analysis. Funnel plot was adopted to assess the publication bias. On the whole, 21 studies comprising 7041 COVID-19 cases were included. As revealed from the meta-analysis, 14.0% (984/7027) of cases had a history of smoking, and 9.7% (675/6931) were subject to underlying cardiovascular diseases. Cases with a history of smoking achieved a higher rate of COVID-19 disease progression as opposed to those having not smoked [OR = 1.53, 95%CI: 1.29 -1.81, P < 0.00001], while no significant association could be found between smoking status and COVID-19 disease progression [OR = 1.23, 95%CI: 0.93 -1.63, P = 0.15]. Besides, smoking history elevated the mortality rate by 1.91-fold [OR = 1.91, 95%CI: 1.35 -2.69, P = 0.0002]. Moreover, underlying cardiovascular disease elevated the incidence of severe disease by 2.87-fold [OR = 2.87, 95%CI: 2.29 -3.61, P < 0.00001] and mortality by 3.05-fold [OR = 3.05, 95%CI: 1.82 -5.11, P < 0.0001] in COVID-19 cases. As demonstrated from the current evidence, smoking displays a strong association with COVID-19 disease progression and mortality, and intensive tobacco control is imperative. Moreover, cases with cardiovascular disease show a significantly elevated risk of disease progression and death when subject to COVID-19. However, the association between COVID-19 and cardiovascular disease, and the potential effect exerted by smoking in the development of the two still require further verifications by larger and higher quality studies.

show abstract

“…Mental healthcare is also an important issue for COV- A COVID-19 Clinical Trial/Clinical Research Task Force comprising mainly members from the Clinical and Translational Research Center was established to support the safety and rapid implementation of large numbers of observational studies, specific clinical studies and clinical trials related to COVID-19. [2][3][4][5][6][7] A Keio COVID-19 Registry was also established to unify multiple studies to develop a database that could provide large amounts of research data in the future. A large-scale nationwide team was established to study genomic susceptibility of the host genome focusing on the low number of serious and fatal cases among Japanese patients.…”

Section: Initiatives For Covid-19 Treatment and Researchmentioning

confidence: 99%

Outbreak of Health Care-associated Novel Coronavirus (SARS-coV-2) COVID-19 infections in the Spring of 2020

Kitagawa

2021

Keio J. Med.

View full text Add to dashboard Cite

show abstract

Clinical characteristics of 345 patients with coronavirus disease 2019 in Japan: A multicenter retrospective study

Cited by 28 publications

References 8 publications

Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

Japan COVID-19 Task Force: a nation-wide consortium to elucidate host genetics of COVID-19 pandemic in Japan

Association of smoking and cardiovascular disease with disease progression in COVID-19: a systematic review and meta-analysis

Outbreak of Health Care-associated Novel Coronavirus (SARS-coV-2) COVID-19 infections in the Spring of 2020

Contact Info

Product

Resources

About